Wilsons Equity Research Report Issued with Buy Rating
Wilsons Equity Research Report Issued with Buy Rating
Sydney, June 8, 2017 AEST (ABN Newswire) - Wilsons maintain a BUY rating and $1.66 price target. Anatara's (ASX:ANR) recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H. Behind the scenes, Zoetis' evaluation work with Detach is ongoing and we are comfortable that Anatara has done the work in supporting that. If Zoetis does exercise its option to license Detach, then we see potential valuation upside to $2.50 per share.

Zoetis is already calling out a negative impact on their medicated feed additive sales just three months into the Veterinary Feed Directive rules coming into force, which switched key swine and cattle products from over-the-counter to prescription only. Zoetis has led the industry on the "antibiotic stewardship" issue and we think it has genuine intentions towards making Detach available to producers.

Wilsons Equity Research

Issued by Wilsons Advisory and Stockbroking Limited ABN 68 010 529 665 - Australian Financial Services Licence No 238375, a participant of ASX Group and should be read in conjunction with the disclosures and disclaimer in this report. Important disclosures regarding companies that are subject of this report and an explanation of recommendations can be found at the end of this document.

To view the Research Report, please visit:
http://abnnewswire.net/lnk/3696T3S9


About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com.

    


Contact

Shane Storey
shane.storey@wilsonsadvisory.com.au
Tel. +61 7 3212 1351



Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 10) (Last 30 Days: 47) (Since Published: 2653) 
ANALYTICS: LOGIN HERE

Anatara Lifesciences Ltd NEWS: RECENT VISITS (5361)

Research Report

Social Media